Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerability of Sacubitril/Valsartan in HFrEF
NCT05387967Phase 4Completed
- Sponsor
- National Institute of Cardiovascular Diseases
- Start
- Jan 2021
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of sacubitril + valsartan in heart failure with reduced ejection fraction (HFrEF), sponsored by National Institute of Cardiovascular Diseases. Started Jan 2021; status: completed.
02
Drugs
sacubitril + valsartan
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on NCT05387967.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05387967.